Purpose of review: Patients with cervical cancer represent a vulnerable population with limited chemotherapeutic options. This year, two large trials focusing on detection/screening and treatment of advanced stage cervical cancer were featured in the opening plenary session of the American Society of Clinical Oncology Annual Meeting. As such, a review of the evolution of chemotherapy in the treatment of this disease is warranted.
Recent findings: Following the establishment of cisplatin as an effective single-agent regimen in patients with advanced stage, recurrent, or persistent cervical cancer, several platinum-containing combinations were studied. Ultimately, the adoption of cisplatin chemosensitizing radiation resulted in relative ‘cisplatin resistance’ and the concept of nonplatinum doublets emerged as an active area of investigation.
Summary: In an era of biologics, combined therapy with cytotoxic drugs and molecular targeted agents, as well as the use of nonplatinum doublets, represent an exciting area yet to be fully explored.
Irvine Medical Center, University of California, Orange, California, USA
Correspondence to Dr Krishnansu Tewari, Professor and Director of Research, Department of Obsterics and Gynecology, Division of Gynecologic Oncology, Irvine Medical Center, University of California, 101 The City Drive South, Orange, CA 92868, USA. Tel: +1 714 456 8020; fax: +1 714 456 7754; e-mail: email@example.com